Core Viewpoint - Haohai Biology is expanding its business by acquiring a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.35 million yuan, aiming to enter the high-value medical device sector of biological amniotic membrane, despite Ruiji's ongoing financial losses and lack of performance guarantees in the transaction [1][3]. Group 1: Acquisition Details - The acquisition involves Haohai Biology purchasing 8.4661 million shares of Ruiji, which has been struggling with losses of 11.77 million yuan last year and 11.29 million yuan in the first three quarters of this year [1][2]. - The transaction does not grant Haohai Biology control over Ruiji's existing team or decision-making on financial and operational matters, as the stake does not allow for consolidation in Haohai's financial reports [2]. Group 2: Financial Performance of Haohai Biology - Haohai Biology's core business has been under pressure, with a revenue decline of 7.12% and a net profit drop of 10.29% in the first half of this year compared to the previous year [1][5]. - The company reported a revenue of 2.698 billion yuan and a net profit of 420 million yuan last year, with growth rates slowing significantly [5]. - In the first three quarters of this year, Haohai's revenue was 1.899 billion yuan, down 8.47%, and net profit was 305 million yuan, down 10.63% [7]. Group 3: Market Context and Competition - The global amniotic membrane market is projected to grow from over 1.89 billion dollars last year to 3.97 billion dollars by 2034, with a compound annual growth rate of approximately 7.7% [8]. - Competition in the biological amniotic membrane sector is intensifying, with other companies like Guangzhou Ruitai Biological and Chengdu Qingshan Likang Pharmaceutical also entering the market [9]. - Analysts suggest that while the acquisition may provide strategic benefits, the ongoing losses and competitive landscape present significant challenges for Haohai Biology [9].

Core Viewpoint - Haohai Biological Technology (昊海生科) plans to invest in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. (瑞济生物) to enter the high-value biological amniotic membrane market despite experiencing a decline in revenue and net profit [1][4]. Group 1: Investment Details - Haohai will acquire a total of 19.8% of Ruiji Biological's shares through a framework agreement, paying 38.35 million yuan and 4.76 million yuan in three phases for 8.4661 million shares and 1.0499 million shares respectively [1][3]. - The transaction price is set at 4.53 yuan per share, based on the market price before Ruiji Biological's delisting from the National Equities Exchange and Quotations [3][9]. Group 2: Company Background - Ruiji Biological, established in 2002, specializes in the production and sale of biological amniotic membranes, which are classified as Class III medical devices used in orthopedic and ophthalmic fields [1][3]. - Haohai aims to enhance its product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors by obtaining distribution rights for Ruiji's products in China [3][9]. Group 3: Financial Performance - Ruiji Biological reported revenues of approximately 46.36 million yuan and 46.09 million yuan for 2024 and the first three quarters of 2025, respectively, with net losses of 11.77 million yuan and 11.29 million yuan [4][10]. - Haohai's revenue for the first three quarters of this year was about 1.899 billion yuan, a year-on-year decrease of 8.47%, with a corresponding net profit of approximately 305 million yuan, down 10.63% year-on-year [4][10]. Group 4: Risks and Challenges - The transaction does not include performance commitments or earn-out arrangements, which means there are risks associated with potential underperformance of Ruiji Biological [4][10]. - Market conditions and sales channels may affect the sales performance of the acquired products, posing risks of reduced investment returns and failure to achieve acquisition objectives [5][10].

Core Viewpoint - Haohai Biological Technology (688366) plans to enter the high-value biological amniotic membrane market despite a decline in revenue and net profit, through acquiring a 19.8% stake in Ruijibio [1][3][5]. Group 1: Company Acquisition Details - Haohai Biological signed a share transfer framework agreement to acquire shares from Ruijibio's existing shareholders for a total of approximately 43.91 million yuan [1]. - The acquisition price is set at 4.53 yuan per share, based on the market price before Ruijibio's delisting from the National Equities Exchange and Quotations [3]. - Ruijibio specializes in producing and selling biological amniotic membranes, which are classified as Class III medical devices used in orthopedic and ophthalmic fields [1][3]. Group 2: Financial Performance - Ruijibio reported revenues of approximately 46.36 million yuan and 46.09 million yuan for 2024 and the first three quarters of 2025, respectively, with net losses of 11.77 million yuan and 11.29 million yuan [4]. - Haohai Biological's revenue for the first three quarters of this year was approximately 1.899 billion yuan, a year-on-year decrease of 8.47%, while net profit was about 305 million yuan, down 10.63% year-on-year [5]. Group 3: Strategic Implications - The investment in Ruijibio is expected to enhance Haohai Biological's product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [3]. - The biological amniotic membrane materials possess human-derived biological characteristics, providing a significant technological and material foundation for research and development in regenerative medicine and tissue engineering [3].

Core Viewpoint - Haohai Biology has acquired a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.35 million yuan, aiming to enter the high-value medical device sector of biological amniotic membranes, despite Ruiji's ongoing financial struggles and lack of performance guarantees in the transaction [1][4]. Group 1: Acquisition Details - The acquisition involves Haohai Biology purchasing 8.4661 million shares of Ruiji, which has been facing financial difficulties with losses of 11.77 million yuan in 2024 and 11.29 million yuan in the first nine months of 2025 [1][3]. - The transaction does not include any performance commitments or earn-out arrangements, posing a risk of investment loss if Ruiji's performance declines further [4]. Group 2: Haohai Biology's Business Context - Haohai Biology, the first biopharmaceutical company listed on both the Hong Kong Stock Exchange and the Sci-Tech Innovation Board, has seen a decline in its core business, with revenue and net profit dropping by 7.12% and 10.29% respectively in the first half of 2025 [1][6]. - The company reported a revenue of 2.698 billion yuan and a net profit of 420 million yuan in 2024, but growth has stagnated, with significant declines in its medical aesthetics, ophthalmology, and orthopedics segments [6][7]. Group 3: Market Potential and Competition - The global amniotic membrane market is projected to grow from 1.89 billion USD in 2024 to 3.97 billion USD by 2034, with a compound annual growth rate of approximately 7.7% [8]. - Competition in the biological amniotic membrane sector is intensifying, with other companies like Guangzhou Ruitai Biological and Chengdu Qingshan Likang Pharmaceutical also entering the market [9].

格隆汇12月14日丨昊海生科(688366.SH)发布公告，赵明璟已辞任联席公司秘书、授权代表及法律程序 代理人，自2025年12月12日起生效。黎映彤已获委任为联席公司秘书、授权代表及法律程序代理人，自 同日起生效。 ...

格隆汇12月14日丨昊海生物科技(06826.HK)发布公告，2025年12月12日耗资112.38万港元回购4.23万 股，回购价格每股26.5-26.64港元。 ...

格隆汇12月14日丨昊海生科(688366.SH)发布公告，赵明璟已辞任联席公司秘书、授权代表及法律程序 代理人，自2025年12月12日起生效。黎映彤已获委任为联席公司秘书、授权代表及法律程序代理人，自 同日起生效。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，趙明 璟先生（「趙先生」）已辭任(i)本公司其中一位聯席公司秘書（「聯席公司秘書」）； (ii)根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第3.05 條所規定的本公司之授權代表（「授權代表」）；及(iii)根據上市規則第19A.13(2)條 及公司條例（香港法例第622章）第16部所規定的代本公司於香港接受法律程序送 達文件及通知書的本公司之授權代表（「法律程序代理人」），自2025年12月12日起 生效。 趙先生確認彼與董事會並無任何意見分歧，亦無有關其不再擔任上述本公司職位 之其他事宜需提請本公司股東及聯交所垂注。 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：682 ...

Core Viewpoint - The company Haohai Biological Technology (688366.SH) plans to acquire a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for RMB 38.35 million, enhancing its presence in the high-value medical device sector focused on biological amniotic membranes [1] Group 1: Company Acquisition - Haohai Biological Technology will use its own funds to acquire 8.4661 million shares from shareholders Miao Jiuchang and Miao Chunyu [1] - The acquisition allows Haohai to gain distribution rights for Ruiji's products within China, thereby expanding its product portfolio in the ophthalmology and orthopedics fields [1] Group 2: Business Overview of Ruiji - Ruiji Biological was established in 2002 and specializes in the production and sale of biological amniotic membranes, which are classified as Class III medical devices [1] - The main products include convex and concave amniotic membranes, biological orthopedic amniotic membranes, and wet biological amniotic membranes, used primarily in orthopedic and ophthalmic applications [1] Group 3: Strategic Implications - The acquisition is expected to provide important technical and material foundations for Haohai's research and development in regenerative medicine and tissue engineering [1] - The human-derived biological characteristics of the amniotic materials are anticipated to drive innovation and technological upgrades in subsequent product offerings [1]